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The association between antibodies to neurotropic
pathogens and bipolar disorder
A study in the Dutch Bipolar (DB) Cohort and meta-analysis
Gijsje J. L. J. Snijders1, Hans C. van Mierlo1, Marco P. Boks 1, Marieke J. H. Begemann1, Arjen L. Sutterland2,
Manja Litjens3, Roel A. Ophoff4, René S. Kahn1,5 and Lot D. de Witte1,5
Abstract
Exposure to neurotropic pathogens has been hypothesized to be a risk factor for the development of bipolar disorder
(BD). However, evidence so far is inconsistent. We, therefore, analyzed the seroprevalence and titer levels of IgG
antibodies against several herpesviruses and Toxoplasma gondii (T. gondii) in plasma of 760 patients with a bipolar
disorder, 144 first-degree matched relatives and 132 controls of the Dutch Bipolar (DB) Cohort using ELISA. In addition,
we performed a literature-based meta-analysis on the seroprevalence of IgG antibodies against these pathogens (n=
14). Our results in the DB Cohort and subsequent meta-analysis (n= 2364 BD patients, n= 5101 controls) show no
association between exposure to herpesviruses and bipolar disorder (HSV-1 [adjusted OR 0.842, 95% CI 0.567–1.230],
HSV-2 [adjusted OR 0.877, 95% CI 0.437–1.761], CMV [adjusted OR 0.884 95% CI 0.603–1.295], EBV [adjusted OR 0.968
95% CI 0.658–1.423]). In the DB Cohort, we did not find an association between bipolar disorder and T. gondii titer or
seroprevalence either [adjusted OR 1.018, 95% CI 0.672–1.542]. The overall OR was not significant for T. gondii [OR: 1.4,
95% CI 0.95–1.90, p= 0.09), but subgroup analyses in age groups below 40 years showed a significantly increased
seroprevalence of T. gondii IgGs in BD [OR: 1.8 (95% CI 1.10–2.89, p= 0.021]. Our meta-analysis indicates that T. gondii
exposure may be a risk factor for BD in certain subpopulations.
Introduction
Bipolar disorder (BD) is caused by a complex interplay
between genetic and environmental factors. Genetic1–3,
epidemiological4, imaging5, and molecular studies on the
brain, cerebrospinal, and blood samples6–8 have all
described an association between BD and the immune
system. It has therefore been hypothesized that exposure
to certain infections could be one of the environmental
risk factors that contribute to developing BD. An inter-
action between genetic risk factors and these pathogens,
or the immune response elicited by these pathogens, is
thought to be involved in the dysregulation of certain
neuronal circuits, underlying BD.
Neurotropic pathogens have been proposed as the main
candidates for this hypothesis9. This includes several types
of herpesviruses (herpes simplex virus (HSV)-1 and -2),
Epstein-Barr virus (EBV), and cytomegalovirus (CMV), as
well as the intracellular parasite Toxoplasma gondii (T.
gondii). These pathogens are prevalent in humans
worldwide, are capable to cross the blood–brain barrier to
cause a latent infection and as such may influence CNS
functions during periods of (re-)activation10. This
neurotropic-pathogen hypothesis is supported by several
lines of evidence: BD patients have been shown to have
higher rates of chronic infectious diseases11,12; infection of
the central nervous system by these neurotropic patho-
gens can lead to BD-like symptoms, including mania,
depression, and psychosis13,14; exposure of animals to
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neurotropic pathogens, such as T. gondii and HSV, can
induce cognitive and behavioral changes later in life15 and
lead to neurotransmitter abnormalities (dopamine, ser-
otonin, glutamate) that have also been associated with
BD16.
Exposure to these infectious agents can be investigated
by determining the presence of immunoglobulin M or G
(IgM or IgG) class antibodies to these pathogens in blood.
IgM is the first antibody to appear after infection and
produced only in the first phase after exposure. IgG is
produced in a delayed response to a primary infection and
can generally be detected in the blood during the entire
lifespan. Seroprevalence rates of IgG, therefore, represent
exposure to a pathogen during life. An increase of the IgG
titer level after the initial exposure can be indicative for
reactivity, reinfection, or chronicity of infection. Antibody
titer levels of the seropositive cases are therefore thought
to correspond to the activity of the pathogen after expo-
sure. IgG seroprevalence and titer levels have been used to
study the relation between BD and these neurotropic
pathogens in various previous studies17–32. T. gondii
stands out as the infection with the strongest evidence.
Sutterland et al. performed a meta-analysis of 11 studies
that assessed the seroprevalence of T. gondii antibodies in
BD. The authors found a significantly higher prevalence of
T. gondii antibodies with an overall odds ratio (OR) of 1.5
(ref. 32), but the heterogeneity of the results was high. The
mean age of participants and publication of a study in a
peer-reviewed journal explained a majority of this var-
iance. These findings are consistent with another more
recent meta-analysis on eight studies showing that T.
gondii infection is associated with BD (OR 1.26, 95% CI
1.08–1.47)33. Only a few studies analyzed the association
between BD and IgG titers to T. gondii. One study found
significantly higher IgG T. gondii titer levels in BD27;
however, several other studies did not find any differ-
ences24,25,34,35. Weaker evidence is available for the neu-
rotropic viruses. The association between BD and the
seroprevalence of herpesviruses HSV-1, HSV-2, CMV is
uncertain. A relation was reported for HSV-1 IgGs and
cognitive functioning20,21,30,36, whereas CMV IgG’s were
associated with hippocampus volume22, telomere
length19, or certain genetic risk factors in BD34. However,
a majority of the case–control studies did not provide
evidence for a direct link between these infectious agents
and BD24,25,27,34. Individual studies may be underpowered
for reliable comparisons and the excess of nominally
significant results with an almost consistent direction of
higher levels of seropositivity or titer may support the
infection hypothesis of BD27,33,34. Because of small sample
sizes, correction for confounders such as age, gender,
ethnicity, and other factors was not always possible in
previous studies and could have contributed to incon-
sistent results. Another complicating factor is the
variability of the prevalence rates of herpesviruses and T.
gondii between different regions. Worldwide ser-
oprevalences of herpesviruses and T. gondii vary between
<5% and >95% depending on environmental and socio-
economic conditions, as well as certain habits and health-
related practices37–39. National seroprevalence rates in the
Netherlands are around 50–75% for HSV-1 (ref. 40),
1–25% for HSV-2 (ref. 40), 85–95% for EBV, 40–95% for
CMV41, and 40% for T. gondii42.
Thus, although exposure to neurotropic pathogens has
been repeatedly proposed as an environmental risk factor
for BD, the supporting evidence remains inconsistent. The
aim of this study was, therefore, to further examine the
role of these infections. We first investigated whether the
seroprevalences or titers of HSV-1, HSV-2, EBV, CMV,
and T. gondii IgG were increased in patients with BD
compared to healthy controls using plasma samples of
participants of the Dutch Bipolar (DB) Cohort. Using a
large number of comprehensively phenotyped BD type I
patients, first-degree relatives, and healthy controls of
Dutch ancestry, this study constitutes the largest number
of individuals so far. To minimize the effect of possible
confounders such as household, socioeconomic status,
educational level, and urbanicity we included a group of
matched first-degree relatives who shared a household
with BD participants as “intermediate” control group and
assessed whether neurotropic pathogens are associated
with BD occurrence.
In order to put our results in perspective to the previous
studies, we subsequently performed a systematic review
and meta-analysis on all published studies that measured
seroprevalences of IgG class antibodies against HSV-1,
HSV-2, EBV, CMV, and T. gondii in well-characterized
cohorts of BD patients in comparison to healthy controls.
Studies were quantitatively summarized and combined in
a meta-analysis where possible. Consequently, by adding
new data from a large BD cohort to previous results, this
study aims to provide a comprehensive and updated
analysis of the evidence for an association between
exposure to neurotropic pathogens and BD.
Material and methods
Study population
The DB Cohort study, started in 2011, is a multicenter
case–control study in the Netherlands, investigating
genetic and phenotypic information of patients with BD
type I, first-degree relatives, and controls. Study design
and recruitment procedure have been described in detail
elsewhere43. In brief, patients with BD, their first-degree
family members and healthy controls were recruited via
clinicians, the Dutch BD patients’ association, pharmacies,
advertisements, and through individuals who previously
participated in scientific studies. Inclusion criteria for
study subjects were: age ≥ 18 years, at least three Dutch-
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born grandparents, and a good command of the Dutch
language. Subjects were excluded from analyses in case of
a somatic illness that could have influenced the diagnosis
of BD. Psychiatric status of BD patients was determined
based on the Structured Clinical Interview for DSM-IV
(SCID-I)44. To assess psychopathology, first-degree rela-
tives of BD patients and healthy controls were evaluated
by use of Mini-International Neuropsychiatric Inter-
view45. Plasma samples were collected from a subgroup of
participants of this cohort during the clinical assessments
between 9 AM and 5 PM. Plasma samples were frozen
and stored at −80 °C prior to determination of IgG class
antibodies against HSV-1, HSV-2, EBV, CMV, and T.
gondii. Plasma-material was available from 760 BD
patients and 132 healthy controls. To minimize effects of
possible confounders (household, urbanicity, socio-
economic status) on the outcome, bipolar patients (n=
144) were age- and gender-matched with a first-degree
relative (n= 144) to assess whether neurotropic
pathogens are associated with BD occurrence. The Med-
ical Ethical Review Committee Utrecht approved the
study (METC: 10–285). Written informed consent was
obtained from all subjects after a complete description of
the study was given. Demographic characteristics are
displayed in Table 1 and Supplementary Table 1.
Measurement of IgG antibodies against HSV-1, HSV-2, EBV,
CMV, and T. gondii
IgG class antibodies against HSV-1, HSV-2, EBV, CMV,
and T. gondii were analyzed using commercial enzyme-
linked immunosorbent assay (ELISA) tests (IBL Labora-
tories, Hamburg, Germany) according to the manu-
facturer’s protocols and further described by De Witte
et al.46. The sensitivity and specificity of the tests are
above 95% for HSV-1, EBV, CMV, and T. gondii. For
HSV-2 the sensitivity is 87.5% and specificity 94.1%. For
the qualitative interpretation of the results, we used the
cut-off control sample provided as standard within the
Table 1 Demographic characteristics, seropositivity, and IgG titer levels of HSV-1, HSV-2, CMV, EBV, and TG in bipolar
disorder patients and controls.
Patients (n= 760) Controls (N= 132) p value p value adjusted*
Mean age (SD) in years 49.41 (12.37) 49.45 (12.80) p= 0.948
Range 18–79 18–79
Gender M/F (% males) 335/425 (44.1) 74/85 (56.0) p= 0.615
Diagnosis BD type I 1 748 Unipolar disorder 10
BD type II 12 Anxiety disorder 7
Other disordersa 13
No disorder 100
Unknown 22
Mean duration of illness in years 18.42 (10.9)
Range 1–51
Seropositivity positive/negative cases (% positive cases)
HSV-1 367/393 (48.2%) 58/74 (43.9%) p= 0.356 p= 0.374
HSV-2 71/689 (9.3%) 10/122 (7.6%) p= 0.514 p= 0.713
CMV 325/435 (42.7%) 52/80 (39.3%) p= 0.469 p= 0.527
EBV 480/280 (63.2%) 83/49 (62.9%) p= 0.951 p= 0.868
TG 275/485 (36.2%) 48/84 (36.3%) p= 0.968 p= 0.932
Median levels (interquartile range)
HSV-1 IgG 34.42 (27.61) 30.46 (33.48) p= 0.210 p= 0.257
HSV-2 IgG 25.55 (26.68) 15.56 (11.17) p= 0.100 p= 0.116
CMV IgG 47.13 (27.13) 51.83 (24.63) p= 0.443 p= 0.204
EBV IgG 16.31 (5.23) 17.39 (5.85) p= 0.154 p= 0.339
TG IgG 225.74 (191.17) 229.61 (190.59) p= 0.894 p= 0.896
*P value adjusted for age and gender
aOther disorders include ADHD, adjustment disorder, eating disorder, substance abuse
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ELISA kit. Samples with scores above the control cut-off
value were scored positive and below as negative. Ser-
opositive samples were further analyzed to determine the
IgG plasma titer levels and expressed as units/ml fol-
lowing the manufacturer’s protocols, in which IgG levels
for CMV, HSV-1, and HSV-2 are quantified by calculating
(patient absorbance value × 10)/(absorbance value of the
cut-off), and IgG levels for EBV and T. gondii are deter-
mined by using the calibration curve provided with the
test and expressed as units/ml. Samples were analyzed
blinded for diagnostic or clinical information.
Statistical analysis
Statistical analysis was performed using SPSS 23.0. All
variables were tested for homogeneity of variances and
normality of distribution by means of the Levene and
Kolgomorov–Smirnov tests, respectively. For sample
characteristics, chi-square tests were used to evaluate
categorical data; independent t-tests were performed for
continuous data. The seroprevalence of IgG antibodies
was analyzed as a dichotomized variable (positive/nega-
tive) with a chi-square test for BD as compared to con-
trols. The differences in seroprevalence between BD
patients and first-degree relatives were also tested using
McNemar’s test. Logistic regression was performed to
determine the odds for IgG positivity in BD as compared
to controls and siblings while adjusting for age and gen-
der. Plasma titers of positive cases were compared using
non-parametric testing because data were non-normally
distributed. Mann–Whitney U test was used to compare
plasma titers of BD patients and controls and Wilcoxon
Rank test was used to compare BD patients and their
matched first-degree relatives. In order to adjust for age
and gender, a post hoc ANCOVA was performed. In the
case of non-normally distributed residuals, the natural log
transformation (ln) was applied. Overall, ANCOVA ana-
lyses were comparable to outcomes of the non-parametric
statistics. The significance level was set at α < 0.05 (two-
tailed). Results were adjusted for multiple testing using a
Bonferroni correction for ten tests.
Literature search
This quantitative review was performed according to
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA)47. A systematic search was
performed in Pubmed using the following search term:
(bipolar OR manic* OR mania OR mood disorder) AND
(virus OR virus* OR parasite OR parasit* OR toxoplasm*)
(see Supplementary Material). Search cut-off date was 19
March 2019. Pre-specified inclusion criteria were: (1)
human case–control studies, comparing (2) patients with
a current diagnosis of BD, with the exclusion of patients
with unclearly or undefined mood or affective disorders
with (3) healthy controls, characterized by absence of
psychiatric disorders such as affective and psychotic dis-
orders, (4) >10 samples in each study arm; (5) measuring
the seroprevalence of IgG class antibodies against HSV-1,
HSV-2, EBV, CMV or T. gondii; (6) original research,
published in a peer-reviewed journal; (7) written in Eng-
lish. In the case of follow-up data or overlapping samples,
we included outcomes of the largest sample size. A total
of 1954 studies were found. Three authors (G.J.L.J.S., H.C.
v.M., and L.D.d.W.) independently performed the data-
base searches, reviewed title and abstracts, and selected
the articles that appeared to meet the inclusion criteria.
Two independent authors reviewed each of the selected
manuscripts in full (G.J.L.J.S. and L.D.d.W.) (see Supple-
mentary Fig. 1 and Supplementary Table 4). When ser-
oprevalence rates of IgG class antibodies against HSV-1,
HSV-2, EBV, CMV, or T. gondii were not given in the
original article, we contacted the corresponding author
asking if we could obtain raw data. After 2 weeks, a
reminder was sent to authors who did not respond.
Reference lists of retrieved articles and two recently
published meta-analyses were screened for additional
relevant articles (n= 10) and the present study was
included in the meta-analysis. See Supplementary Fig. 1.
Meta-analysis
All analyses were carried out using the Comprehensive
Meta-Analysis48 software developed by Biostat. Five or
more studies were minimally required for meta-analysis.
Unadjusted odds ratio’s (OR) was used to quantify effect
sizes (ES) for the differences between bipolar patients vs. a
control group. Given the heterogeneity among studies, we
used a random effects model for all comparisons49. The
Q-statistic test, displaying a chi-square distribution with
k-1 degrees of freedom, was performed to evaluate the
existence of heterogeneity. Higher Q-values than degrees
of freedom indicates that the variability among studies is
higher than would be expected due to randomness and
further examination of subgroups is warranted. I-squared
(I2) was calculated to estimate the amount of hetero-
geneity. I2 reflects which proportion of the observed
variance reflects differences in true effect size rather than
sampling error (range 0–100%), with an I2 of 25% indi-
cating low, 50% moderate, and more than 75% high het-
erogeneity50. The potential for publication bias was
assessed by visual examination of Funnel plots and by the
Egger’s test (which was considered significant if the one-
sided p value was ≤0.10)51. As ethnicity, methodology, age,
and gender were expected to vary between studies, we
investigated which moderators were associated with the
reported OR’s using random effects meta-regression
analyses. In the case of significant outcomes (p < 0.05),
subgroup analyses were performed. Random effects meta-
regression analyses were conducted. We conducted “one
study removed” and “outlier removed” sensitivity
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analyses52. A-one-study removed sensitivity analysis was
performed by iteratively removing one study at a time to
confirm that our findings were not driven by a single
study48. To reduce the amount of heterogeneity, outlying
studies were removed and the meta-analysis was per-
formed again53. Potential outlier studies were defined as
standardized residual z-scores of effect sizes exceeding
±1.96 (p ≤ 0.05 two-tailed).
Quality check
Several criteria were assessed to evaluate the quality of
the studies that were included in our meta-analysis.
Definition of the study population was qualified as high
(+) when both the patient and control groups were well
described; a structured clinical interview was used to
confirm the diagnosis in patients and exclude psycho-
pathology in controls, and the study population reflects
the source population. The methodological standards
were defined as high when laboratory tests to measure
IgGs and cut-offs were well described. Blinded outcome
measurements were qualified as high when raters were
blind to diagnostic or clinical information. Correction for
confounding factors was scored high when studies cor-
rected for multiple relevant confounding factors and
intermediate (+/−) when correction for only age and
gender was applied. Selection bias refers to systematic
differences between the baseline characteristics of the
groups that were compared. This was rated high if groups
were comparable and low if baseline characteristics were
different. Selective reporting is qualified low when
important details regarding the study population or out-
come “seroprevalence” could not be retrieved from the
study. We identified the following potential confounders
(age, gender, ethnicity, psychotropic medication, disease
state, socioeconomic, household, and lifestyle factors). We
checked the description of these variables and whether
they were restricted for by matching or statistical analyses
in the included studies (see Supplementary Table 3).
Results
DB Cohort
Characteristics of included BD patients and controls are
summarized in Table 1. Seroprevalence rates for HSV-1
[adjusted OR 0.84, CI 95% 0.57–1.23], HSV-2 [adjusted
OR 0.88, 95% CI 0.44–1.76], CMV [adjusted OR 0.88, 95%
CI 0.60–1.30], EBV [adjusted OR 0.97, 95% CI 0.66–1.42],
and T. gondii [adjusted OR 1.02, 95% CI 0.67–1.54]
showed no significant differences between BD patients
and controls while adjusting for age and gender. IgG titer
levels of HSV-1, HSV-2, CMV, EBV, and T. gondii did not
significantly differ between BD patients and controls (see
Table 1). However, the sample size of the control group is
considerably smaller (n= 132) than the BD group (n=
760). To increase our control group to n= 400, we
included 268 healthy controls of Dutch ancestry from the
genetic outcome risk of psychosis cohort. The ser-
oprevalence and titers of this cohort were previously
tested using the same method and described before46.
Increased seroprevalences or titers were not found when
the BD group was compared to the pooled control group
with adjustments for age and gender (data not shown). No
significant differences were detected comparing the pre-
sence of any of the five neurotropic pathogens in BD
patients vs. controls [adjusted OR 1.322, 95% CI
0.706–2.475].
As shown in Table 2 no significant differences between
BD patients and matched first-degree relatives were
identified with regard to IgG class antibodies titers against
HSV-1, HSV-2, EBV, CMV, and T. gondii. We found that
the seroprevalence of HSV-2 is significantly higher in BD
patients (8.3% vs. 4.2%, p < 0.001) and HSV-2 IgG titers
were higher (median 33.10 units/ml (IQR 32.15) vs. 20.47
units/ml (IQR 11.96), p= 0.131, p corr= 0.043) as com-
pared to first-degree relatives. However, the significant
difference in IgG titer level did not survive Bonferroni
correction. Exclusion of control subjects or first-degree
relatives diagnosed with a unipolar depression does not
alter the results (data not shown).
Systematic search
The flowchart in Supplementary Fig. 1. depicts the
results of our systematic search. Fourteen studies inves-
tigating IgG class antibodies against HSV-1, HSV-2,
CMV, T. gondii, and/or EBV were identified, including a
total of 2364 BD patients and 5101 healthy controls. The
age range for the included studies was between 30 and 57
years. Details on the methodological design, number of
participants, and outcome measures for the individual
studies are described in Table 3. A quality assessment of
the studies is provided in Supplementary Table 2.
Meta-analyses herpesviruses
Our systematic search resulted in the inclusion of nine
studies for CMV, seven for HSV-1, five for HSV-2, and
two for EBV (Table 3). A meta-analysis was performed for
CMV, HSV-1, and HSV-2. Figure 1a–c shows that the
seroprevalence of IgG was not significantly increased in
BD for these three viruses (CMV: OR= 1.19, CI 95%
0.85–1.64, p= 0.30; HSV-1: OR 0.92, 95% CI 0.73–1.14,
p= 0.44; HSV-2: OR 1.22, CI 95% 0.86–1.75, p= 0.25).
Inspection of the funnel plots and the Egger’s test did not
show indications for publication bias. The heterogeneity
for the studies on HSV-1 and HSV-2 was low (I2= 18%
respectively I2= 17%), but for CMV heterogeneity was
moderate-high: I2= 56%. The Q-value (p < 0.02) indicated
significant variability between studies for CMV. The
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number of studies on EBV was too low to perform a meta-
analysis. The individual OR of the study of Dickerson
et al.20 just reached significance (p= 0.04), but the present
study was not significant (p= 0.95). We analyzed several
moderators that could potentially have an influence on
CMV, EBV, HSV-1, and HSV-2 seroprevalences, includ-
ing gender, age, the seroprevalence of the control group,
ethnicity (Caucasian or not) or measurement technique.
None of these factors were associated with the OR or
significantly changed heterogeneity for any of the her-
pesviruses. No potential outlier studies were detected for
herpesviruses. Sensitivity analyses with the removal of the
DB Cohort or the other studies showed that removal of
the study of Hamdani et al.26 revealed a significant asso-
ciation between HSV-2 and BD (OR 1.54, 95% CI
1.03–2.30, p= 0.033). Removal of other studies did not
show significant results.
Meta-analysis T. gondii
Eleven studies met the inclusion criteria of our sys-
tematic search for T. gondii. Weight of the included stu-
dies was largely similar (ranging from 5% to 12%), except
for the study of Gerber et al.21. The quality assessment of
the studies is provided in Supplementary Table 2. The
majority of the studies, but not all, matched or corrected
for age and gender and additional confounders relevant to
T. gondii infection, including ethnicity, socioeconomic,
lifestyle and household factors54. Only the studies of
Hamdani26, Tedla24, and the present study in DB Cohort
used structured interviews to confirm a psychiatric diag-
nosis in the patient group and exclude psychopathology in
the control group. Serology assessments were in general
comparable between studies and often performed at the
same laboratory18,20,21,25,34. The overall OR of the meta-
analysis was not significant (OR 1.4 95% CI 0.95–1.90,
Table 2 Demographic characteristics, seropositivity, and IgG titer levels of HSV-1, HSV-2, CMV, EBV, and TG in bipolar
disorder patients and matched first-degree relatives.
Patients
(N= 144)
Matched first-degree
family members (n= 144)
p valuea p value pairwiseb p value adjustedc
Mean age (SD) in years 48.05 (12.75) 54.14 (15.35) p= 0.000
Range 23–79 18–88
Gender M/F (% males) 49/95 (34.0) 45/99 (31.25) p= 0.615
Diagnosis BD type I 143 Anxiety disorder 9
BD type II 1 Depression 30
Psychotic disorder 1
Other disorders* 13
No disorder 92
Mean duration of illness in years 18.0 (11.6)
Range 1–51
Seropositivity positive/negative cases (% positive cases)
HSV-1 62/82 (43.0%) 72/72 (50.0%) p= 0.237 p= 0.468 p= 0.669
HSV-2 12/132 (8.3%) 6/138 (4.2%) p= 0.144 p < 0.001 p= 0.152
CMV 55/89 (38.2%) 68/76 (47.2%) p= 0.121 p= 0.110 p= 0.319
EBV 79/65 (54.9%) 77/67 (53.5%) p= 0.813 p= 0.356 p= 0.678
TG 44/100 (30.5%) 64/80 (44.4%) p= 0.015 p= 0.006 p= 0.266
Median levels (interquartile range)
HSV-1 IgG 30.75 (27.09) 33.72 (24.15) p= 0.386 p= 0.184 p= 0.091
HSV-2 IgG 33.10 (32.15) 20.47 (11.96) p= 0.131 NA p= 0.043
CMV IgG 45.53 (26.56) 51.05 (22.96) p= 0.314 p= 0.228 p= 0.636
EBV IgG 15.78 (5.41) 16.13 (5.28) p= 0.337 p= 0.771 p= 0.803
TG IgG 212.97 (182.76) 190.06 (204.03) p= 0.845 p= 0.426 p= 0.726
NA not applicable aComparison using chi-squared test or Mann–Whitney U test bPaired comparison using McNemar’s test or Wilcoxon Rank test cP value adjusted for
age and gender
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p= 0.09) and the heterogeneity was high (I2= 72%). The
Q-value (p < 0.001) indicated significant variability
between studies (see Fig. 2a). There was no evidence of
publication bias with Egger’s test (p= 0.12), confirmed by
examination of the funnel plot. Removal of the DB Cohort
did not change the results (overall OR 1.41, 95% CI
0.95–2.10, p= 0.09). Removal of the “negative” study ofTa
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Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Avramopoulos 0,865 0,649 1,152 0,320
Dickerson 2,734 1,436 5,207 0,002
Gerber 1,286 0,358 4,617 0,700
Hamdani 0,686 0,435 1,084 0,107
Prossin 1,832 1,086 3,089 0,023
Rizzo 1,333 0,168 10,579 0,785
Snijders 1,149 0,788 1,677 0,470
Tanaka 1,000 0,347 2,878 1,000
Tedla 0,822 0,033 20,389 0,905
1,185 0,856 1,642 0,307
0,01 0,1 1 10 100
Favours HC Favours BD
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Avramopoulos 0,866 0,655 1,146 0,315
Dickerson 0,846 0,494 1,449 0,542
Gerber 1,143 0,368 3,547 0,817
Hamdani 0,656 0,408 1,055 0,082
Snijders 1,191 0,821 1,728 0,356
Tanaka 1,711 0,615 4,760 0,303
Tedla 0,140 0,008 2,453 0,178
0,917 0,735 1,145 0,445
0,01 0,1 1 10 100
Favours HC Favours BD
OVERALL 
OVERALL 
Herpes simplex virus-1 (HSV-1) 
Cytomegalovirus (CMV) A 
B 
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Dickerson 1,707 0,909 3,205 0,096
Gerber 2,923 0,302 28,286 0,354
Hamdani 0,795 0,478 1,321 0,376
Snijders 1,257 0,631 2,505 0,515
Tedla 1,598 0,699 3,654 0,267
1,228 0,860 1,754 0,258
0,01 0,1 1 10 100
Favours HC Favours BD
Herpes simplex virus-2 (HSV-2) 
OVERALL 
C 
Fig. 1 Bipolar disorder and prevalence of IgG antibodies against
Cytomegalovirus, Herpes simplex virus-1, and Herpes simples-
virus-2. Meta-analysis on a cytomegalovirus (CMV) (n= 9), b herpes
simplex virus-1 (HSV-1) (n= 7), c herpes simplex virus-2 (HSV-2) (n= 5)
in bipolar disorder. BD bipolar disorder, HC healthy controls.
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Avramopoulos revealed a significant positive association
between T. gondii and BD (OR 1.5, 95% CI 1.18–1.92, p=
0.001). Two positive26,29 and one negative34 studies were
identified as potential outliers. Removal of these three
potential outliers resulted in a significant positive asso-
ciation between T. gondii and BD (OR 1.28, 95% CI
1.03–1.92, p= 0.03).
Potential moderators T. gondii
To assess which moderators influenced the outcome of
the meta-analysis, we first investigated which moderators
were associated with the reported ORs in the included
studies. No significant relation of ethnicity, male gender,
seroprevalence rates of the control population, and mea-
surement technique with the value of the OR was found.
For mean age (as reported by 10 of the 11 studies) a
negative association was observed (intercept= 2, 82,
slope=−0.06, p= 0.003). A subgroup analysis was per-
formed post hoc. At first, the study samples were divided
into two age categories based on the mean age (in years)
of the studies included in the meta-analysis (<40 years and
>40 years).
Significant higher seroprevalence of T. gondii was
found for BD in age group <40 years with an overall OR
of 1.8 (95% CI 1.10–2.89, Q (4)= 3.8, p= 0.021, I2=
0%). Heterogeneity was absent in this subgroup,
although the forest plot showed considerable variation
in ORs. No significant differences were found in the
group aged >40 years and overall OR was 1.1 (95% CI
0.70–1.76, Q (4)= 21.8, p= 0.64, I2= 82%) (see Fig. 2b).
The differences in OR between the two age groups was
not significant (p= 0.174).
Fig. 2 Bipolar disorder and prevalence of IgG antibodies against T. gondii. a Meta-analysis on Toxoplasma gondii (T. Gondii) (n= 11) in bipolar
disorder. b Subgroup analysis (age > 40 years and age < 40 years) on Toxoplasma gondii (T. gondii) in bipolar disorder (n= 10). Two age categories
were based on the mean age (in years) of the included studies in the meta-analysis (<40 years and >40 years).
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Discussion
In this study, we investigated whether infection with
neurotropic pathogens could be one of the environmental
factors that in interaction with genetic background con-
tributes to BD. The seroprevalence, which reflects prior
exposure to a certain pathogen, of none of these IgGs was
increased in BD patients as compared to healthy controls
or siblings in the DB Cohort. The titer levels of IgGs to
these pathogens were also not increased in patients
compared to controls or siblings, although we found
higher HSV-2 seroprevalence rates and titers in patients
compared to siblings only. To draw a more general con-
clusion on the results of this and previous studies we
subsequently performed a systematic review and meta-
analysis for the seroprevalences of these pathogens in BD.
The hypothesis of neurotropic pathogens as causing or
contributing factor in BD was based on studies that have
described immune alterations in BD1–8. Low-grade
inflammation has been documented in BD. Increased
levels of pro-inflammatory cytokines and acute phase
proteins have been shown during acute mood episodes
and in later stages of the disease55–60. Furthermore, stu-
dies have shown antidepressant effects of anti-
inflammatory medication in the treatment of a bipolar
depression61. Neurotropic pathogens may be one factor
that plays a role in this inflammatory process through
activation of the adaptive and innate immune systems.
This phenomenon has been described extensively for
schizophrenia62, in particular in specific subgroups of
patients (cognitive impairers, smokers)23,63,64.
Our results on the seroprevalences of herpesviruses in
the DB Cohort are in line with the findings from the meta-
analysis, showing no association between BD and IgG
prevalence to any of these viruses. For HSV-1 and HSV-2
none of the previous studies showed a significant asso-
ciation with BD. The heterogeneity of results on these
viruses is low, with the exception of CMV. Two previous
studies with a moderate sample size found an increased
seroprevalence of CMV18,20. Our current analysis and
meta-analysis did not confirm this association. In the
studies of Prossin and Dickerson considerable differences
between groups were reported for age, ethnicity, and
gender. It is not clear from the methodology whether
adjustments for these potential confounders were made.
Sensitivity analyses showed that the removal of the study
of Hamdani et al.26 revealed a significant positive asso-
ciation between HSV-2 and BD. We compared study
design, age, gender, methodology, and ethnicity between
the study of Hamdani and the other studies. We did not
observe obvious reasons for these contrasting results.
Our results of no increased seroprevalence of T. gondii
in BD were in line with the results of our meta-analysis.
We did, however, detect a high heterogeneity between
studies. We found that age was significantly associated
with the ORs in the different studies and explained part of
the heterogeneity. The negative association between OR
and age suggest that only in younger cohorts a significant
effect could be detected and that this effect is lost when
the seroprevalence of T. gondii increases in an aging
population. We could confirm this hypothesis by a post
hoc subgroup analysis in age groups <40 years and >40
years, but could not validate this hypothesis by analyzing a
younger subgroup of <40 years (n= 411) in the DB
Cohort (data not shown). It would, however, be interest-
ing to examine a high risk or first-episode BD cohort for
T. gondii IgGs. Three studies were “potential” out-
liers26,29,34 and removal of these studies resulted in a
significant positive association between T. gondii and BD.
We compared these three potential outlier studies in
order to explain differences in OR. The seroprevalence of
T. gondii was considerably higher in the study of Hamdani
(74.6%)26, compared to the study of Avramopoulos
(11.7%)34. The difference between the two groups in
seroprevalence rates may be explained by differences in
the two populations in risk behavior for acquiring T.
gondii such as ingestion of raw meat and unpasteurized
milk products, as well as contacts with cats. Most T.
gondii studies did not restrict for these factors. Further-
more, Hamdani et al.26 and Chen et al.29 included control
participants that were on average 18 years younger than
the controls in the study of Avramopoulos. This finding
underscores the hypothesis that only in younger cohorts a
significant effect may be detected, which is in line with
findings in our meta-analysis. Previous literature suggests
that T. gondii exposure is only a significant risk factor in
regions with a high seroprevalence32. This could be
caused by regional differences in age of exposure, which is
lower in regions with higher seroprevalences, as well as
the type of T. gondii strain. However, in our meta-analysis,
we could not replicate the significant relation between the
moderator seroprevalence rates of the control population
and the OR.
Sutterland et al.32 and de Barros et al.33 previously
performed a meta-analysis on T. gondii seroprevalences in
BD and found a significant odds ratio of 1.52 (95% CI
1.06–2.18, p= 0.002) and 1.26 (95% CI 1.08–1.47),
respectively32,33. In these studies, the heterogeneity was
also high (I2= 67% and I2= 55%, respectively). Sutterland
et al. (2015) showed that the high heterogeneity was
mostly explained by (un)published data and age adjust-
ment. Similar to our meta-analysis, no signs of publication
bias were observed by Sutterland and colleagues. Only a
few studies overlapped between the three meta-analyses.
We included several studies with a large sample size that
were published after the meta-analysis of Sutterland et al.
and de Barros et al. (2017)25,26,28,29 and only included
published papers, studies with sample sizes >10 and
case–control studies. Sutterland et al.32 included
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unpublished studies and studies analyzing neonatal blood
spots, which examines T. gondii antibody status of the
mother of patients with BD. De Barros et al.33 2017
included studies with overlapping samples. Altogether,
these differences may explain the low overlap of included
studies and differences in results between the three meta-
analyses on T. gondii.
Additionally, we did not find an association between
IgG titer levels to neurotropic pathogens and BD. We
found higher seroprevalence rates and HSV-2 titers in
patients compared to first-degree relatives, but not to
controls. Six other studies have assessed HSV-2 and found
no significant differences in seroprevalence or titers
between patients and controls only17,18,20,21,24,26 (see
Supplementary Table 5). A possible explanation is that
bipolar persons are more likely to engage in risky sexual
behavior that places them at risk of sexually transmitted
infections such as HSV-2 (ref. 65). The inconsistent results
could be explained by small sample sizes, especially the
measurement of IgG titer is based on subjects that are
positive for antibodies, which is low for HSV-2. Previous
studies measured titer levels in the total study population,
while we assessed the titer level only in seropositive cases.
Therefore, a direct comparison of titer levels between
studies should be interpreted with some caution. Our
results are in contrast to two recent other positive studies
on CMV titers with smaller sample sizes18,19. Rizzo et al.
showed increased IgG titers in euthymic patients with BD,
while Prossin et al. mentioned that CMV IgG was higher
in BD type I patients with elevated moods compared to
euthymic BD patients. CMV titers rise steeply between
the age of 41 and 50 years in the general population66. In
the present study, the included BD and HC participants
were 5–10 years older than participants included in the
two previous studies. We cannot exclude that CMV titer
level differences between BD and HC subjects have
diminished over time. Our results are in line with four
other large studies on T. gondii20,24,25,34. Only one smaller
study, performed in France, showed a significant differ-
ence in T. gondii IgG titer levels between groups27. The
significant higher titer levels in the BD group might be
attributed to the higher mean age in this group compared
to controls (44 and 38 years, respectively). Previous stu-
dies showed that T. gondii infection increased significantly
after 40 years of age in the French population67. Due to
the differences in titers with age, future studies should
analyze titer levels stratified for age. Another point of
importance is the assumption that higher titer levels are
indicative for reactivity, reinfection or chronicity of
infection. Since our data are cross-sectional, we cannot
distinguish between these different processes.
Strong aspects of our antibody analyses in the DB
Cohort are the sample size of the patients, which is the
largest to date and that we controlled for age, gender,
and ethnicity. Furthermore, the inclusion of a group of
first-degree relatives as “intermediate” control group
also minimizes the effects of possible confounders on
seropositivity as many potential confounders such as
ethnicity, household, educational level, and urbanicity
are shared. Limitations of our study are the small sample
size of the healthy controls that were included from the
DB Cohort. To overcome this problem we included
controls from a previous study which used a similar
methodology except for the time of sample collection
and testing. Like most previous studies, we did not
analyze data on several potential confounders, such as
the size of household, urbanicity, contact with felines,
and raw meat consumption. Moreover, we analyzed
previous exposure to pathogens by analyzing IgG in
blood years after disease onset. Since it is hypothesized
that these pathogens play a role in the development of
BD, it would be interesting to repeat this study in first-
episode BD patients and include the measurement of
IgM type antibodies.
We limited the study to five pathogens; therefore, this
study cannot exclude a role for other neurotropic
pathogens. Another strong aspect of our study is the
addition of a systematic review and meta-analysis, which
provides an overview of the current evidence on the
association between exposure to neurotropic pathogens
and BD. In contrast with previous meta-analyses, we
carefully selected case–control studies with at least
moderate sample sizes and excluded cohort studies which
assessed the seroprevalence of mothers. However, this
part of our study also has several limitations. First of all,
we were unable to retrieve all relevant data, as not all
authors responded to our request for additional infor-
mation. Second, despite careful analysis of possible
moderators, significant heterogeneity remained for the
meta-analysis on CMV and T. gondii, which suggest that
other moderators play a role. This could include differ-
ences in laboratory methodologies, such as assays used or
cut-off values applied, but also other confounders related
to exposure to these pathogens. Low educational level,
having children, crowding, low household income and
factors related to lifestyle (raw meat consumption, contact
with felines, and promiscuity) are risk factors for an
increased seroprevalence of neurotropic pathogens68–70.
Several clinical variables should also be taken into
account, such as disease state and severity, use of (psy-
chotropic) medication, and duration of illness. Unfortu-
nately, we could not analyze these factors in the meta-
analysis due to inconsequent reporting and limited data.
Finally, the data incorporated in the present meta-analysis
might be incomplete, since we decided not to include
unpublished data as these studies are not peer-reviewed
and their internal validity may be difficult to assess (due to
poor reporting).
Snijders et al. Translational Psychiatry           (2019) 9:311 Page 11 of 13
In conclusion, the data presented in this study did not
provide robust evidence for an association between
exposure to herpesviruses and BD. Findings on T. gondii
IgGs suggest that there is no association between expo-
sure to this pathogen and BD, however additional studies
are needed in early-onset BD patients and strain-specific
analysis to determine whether T. gondii exposure is an
environmental risk factor for BD or not. Further clarifying
this potential association is of importance, since the link
between T. gondii and BD is not only interesting for
understanding the pathogenesis of BD but may also pro-
vide a target for treatment71.
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